News

Natural Dentist, BreastCancer.org partner to aid cancer patients with oral complications

BY Jason Owen

MADISON, N.J. and ARDMORE, Pa. — The Natural Dentist, a line of therapeutic oral care products, is pleased to announce a new partnership with Breastcancer.org, a leading online expert resource for comprehensive information and support on breast health and breast cancer. The goal of the partnership is to raise awareness about the oral complications that often occur during cancer treatments, and to provide patients with the necessary knowledge and resources to manage these side effects, which can compromise health and quality of life.

During cancer treatment, cells lining the mucus membrane are not replaced as quickly as needed, leaving the mouth especially susceptible to mouth sores, infections, and bleeding gums.

"When a loved one was diagnosed with cancer, I saw personally how mouth pain during treatment could be severe enough to affect a person’s ability to eat, drink, chew, and speak," says Kelly Kaplan, president of Revive Personal Products Company, LLC and distributer of the Natural Dentist. "I’m pleased to partner with Breastcancer.org to raise awareness about this issue and applaud their dedication to helping women and their loved ones understand and manage all aspects of breast cancer."

The Natural Dentist Healthy Gums Mouth Rinse, in particular, is recommended by the medical experts at Breastcancer.org because of its unique combination of medicinal herbs and aloe which both soothe and relieve mouth irritations without artificial colors or flavors, and without alcohol.

"As the leading online resource for breast health and breast cancer, Breastcancer.org provides expert-reviewed information about a range of topics affecting women before, during, and after cancer treatment," says Rita Lusen, vice president of corporate partnerships and marketing for Breastcancer.org. "There is a real need for accurate information about the benefits of proper oral care during cancer treatment, and partners like the Natural Dentist help our organization deliver on the mission and better serve the community-at-large."

To learn more about how good dental hygiene may help prevent or reduce complications before, during, and after cancer treatment, or to request a free sample of the Natural Dentist Healthy Gums Mouth Rinse, please visit: RinseForRelief.com/.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Emdeon, Chain Drug Consortium renew contract for multiple pharmacy solutions

BY Jason Owen

NASHVILLE, Tenn. — Emdeon Inc., a provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced it has been selected to continue providing multiple pharmacy solutions to the Chain Drug Consortium, a collaborative that represents more than 1,000 retail pharmacies nationwide. Among the renewed services, CDC participating pharmacies will be able to utilize the Emdeon Clinical Exchange eRx Network, which is designed to enhance interoperable information exchange and help improve patient safety and clinical outcomes.

"Certainly as we build a model for success with evolving reimbursement models, coordination of care and engaging patients in a meaningful way, we feel confident that Emdeon is a technology leader positioned to help the retail pharmacy succeed," said Robert J. Narveson, president and CEO of Thrifty White Pharmacy.

Through Emdeon’s innovative services, expansive connectivity and industry expertise, pharmacies can be relieved of administrative burdens, empowered to more actively engage patients and enabled to efficiently exchange clinical information. Managing nearly 300 million clinical and pharmacy exchanges annually on the Emdeon Clinical Exchange eRx Network, Emdeon is uniquely positioned to deliver clinical, administrative and financial solutions through pharmacy management systems and across patient-care access points.

"Emdeon has been a trusted partner of the CDC for more than ten years," said Eddie Frisch, president and CEO for Chain Drug Consortium. "We are pleased to renew our commitment to providing participating CDC members with solid pharmacy technology and services and Emdeon’s unmatched customer service."

For more than 30 years, Emdeon has provided a comprehensive suite of both clinical and administrative healthcare solutions. Today, hospitals, physicians, labs, payers and pharmacies use Emdeon’s network to exchange health information more than seven billion times annually. As the single largest clinical, financial and administrative health information exchange in the United States, Emdeon’s network currently reaches approximately 500,000 providers, 81,000 dentists, 60,000 pharmacies, 5,000 hospitals, 1,200 payers and 350 labs.

"We are excited to renew our longstanding relationship with the CDC. The CDC and its members are on the cutting edge of providing pharmacy services that help improve patient care and are demonstrating the value of pharmacies as key members of the patient care team," said Kevin Mahoney, executive vice president of pharmacy services for Emdeon.

Emdeon will be exhibiting its comprehensive suite of pharmacy solutions at booth 2704 during the NACDS technology expo August 12-14, 2013.

To read more about the products and events happening at NACDS Total Store Expo this week, click here.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Teva, Perrigo announce launch of generic temozolomide

BY Jason Owen

JERUSALEM and ALLEGAN, Mich. — Teva Pharmaceutical Industries Ltd., and Perrigo Co. today announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

This product is the generic equivalent to Temodar (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temodar had annual sales of approximately $423 million in the United States, according to IMS data as of December 31, 2012. The launch of this product provides a quality alternative, making cancer therapy more cost effective for patients who suffer from this devastating cancer.

Perrigo’s chairman, president and CEO Joseph C. Papa stated, "This first-to-file launch with our partner Teva is another example of our focus to manufacture complex API’s. We are pleased to offer this important product to patients in the United States."

"We are pleased to partner with Perrigo to offer patients a high-quality, less expensive alternative of this important medicine. This launch demonstrates Teva’s commitment to continue to pursue first-to-market opportunities and enhance the value of our portfolio by concentrating on high-margin, low competition markets," stated Allan Oberman, president and CEO of Teva Americas Generics.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?